ATROVENT NASAL SPRAY 0.03% Rx
Generic Name and Formulations:
Ipratropium bromide 0.03% (21mcg/spray); aqueous soln.
Boehringer Ingelheim Pharmaceuticals
Indications for ATROVENT NASAL SPRAY 0.03%:
Rhinorrhea associated with allergic and nonallergic perennial rhinitis.
Adults and Children:
<6yrs: not recommended. ≥6yrs: 2 sprays in each nostril 2–3 times daily.
Allergy to atropine or its derivatives.
Avoid eyes. Narrow-angle glaucoma. GI or GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Epistaxis, pharyngitis, nasal dryness or irritation, other nasal symptoms, nausea.
Nasal spray—30mL (345 sprays)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Comorbid Narcolepsy and Schizophrenia in Adolescents
- Ketamine in Electroconvulsive Therapy Accelerates Antidepressive Effects
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Prenatal Insecticide Exposure in Mother May Be Linked to Risk for Autism in Children